| Does early letermovir initiation delay engraftment ? | Antimicrobial agents and chemotherapy |  | | 2026 | 8 | 49 |
|
| Integrating killer cell immunoglobulin-like receptor high-resolution genotyping for predicting transplant outcomes in allogeneic hematopoietic stem cell transplantation | Haematologica | | | 2026 | 12 | 23 |
|
| Pretransplant CMV-IgG Titers and DNAemia Are Associated With CMV Infections Post Allogeneic Hematopoietic Cell Transplant With or Without Letermovir | Open forum infectious diseases | | | 2026 | 9 | 44 |
|
| Azacitidine-induced remission enables allogeneic transplantation in TET2/BCOR-mutant relapsed extranodal natural killer/T-cell lymphoma : a case report | Haematologica | | | 2026 | 19 | 76 |
|
| Influence of time-of-day of graft infusion on allogeneic hematopoietic stem cell transplantation outcomes : a validation cohort study | Journal for immunotherapy of cancer | | | 2025 | 8 | 32 |
|
| Blood virome after allogeneic hematopoietic stem cell transplantation | Open forum infectious diseases | | | 2025 | 72 | 157 |
|
| Isolation measures during the COVID-19 pandemic in transplant units may decrease respiratory infection rates and improve non-relapse mortality | Bone marrow transplantation |  | | 2025 | 14 | 0 |
|
| Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients : A Registry Study From the Société Francophone de Greffe de Moelle et Thérapie Cellulaire ( SFGM ‐ TC ) | American journal of hematology | | | 2025 | 7 | 29 |
|
| Epidemiology of hospital-acquired bloodstream infections in haemato-oncology patients in Geneva, Switzerland | Infection | | | 2025 | 45 | 249 |
|
| Utility of the 2024 best practice recommendations from the EBMT Cellular Therapy and Immunobiology Working Party for use of donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation | Bone marrow transplantation | | | 2024 | 92 | 0 |
|
| Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation : a case report | Frontiers in immunology | | | 2024 | 68 | 186 |
|
| Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission : results of a randomized phase III study | Haematologica | | | 2024 | 84 | 107 |
|
| Severe anaphylaxis after chimeric antigen receptor T-cell injection : a case report | EJHaem | | | 2024 | 64 | 192 |
|
| Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021 | Hematological oncology | | | 2024 | 93 | 0 |
|
| Impact of intermittent versus continuous infusions on central line-associated bloodstream infection risk in haemato-oncology patients : a quasi-experimental study | The Journal of hospital infection | | | 2024 | 68 | 401 |
|
| Allogeneic haematopoietic cell transplantation for chronic myeloid leukaemia in Switzerland in the face of rapid development of effective drugs | Swiss medical weekly | | | 2024 | 69 | 32 |
|
| Deuxième allogreffe (mise à jour). Recommandations de la Société francophone de greffe de moelle osseuse et de thérapie cellulaire (SFGM-TC) | Bulletin du cancer | | | 2024 | 64 | 0 |
|
| Pre-engraftment bacteremia after allogeneic hematopoietic cell transplantation without primary fluoroquinolone antibacterial prophylaxis | Transplant infectious disease | | | 2024 | 73 | 200 |
|
| Cefepime trough levels and clinical outcomes in patients undergoing universal therapeutic drug monitoring : A prospective cohort study | CMI communications | | | 2024 | 9 | 28 |
|
| Epidemiology, outcomes and risk factors for recurrence of Clostridioides difficile infections following allogeneic hematopoietic cell transplantation : a longitudinal retrospective multicenter study | Bone marrow transplantation | | | 2024 | 91 | 135 |
|
| NK and T cell repertoire is established early after allogeneic HSCT and is profoundly imprinted by CMV reactivation | Blood advances | | | 2024 | 123 | 138 |
|
| Routine infectious disease consultation prior to an allogeneic hematopoietic cell transplant | Open forum infectious diseases | | | 2023 | 96 | 156 |
|
| Revisiting cytomegalovirus serology in allogeneic hematopoietic cell transplant recipients | Clinical infectious diseases | | | 2023 | 110 | 245 |
|
| Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption | Frontiers in oncology | | | 2023 | 81 | 176 |
|
| Allogeneic hematopoietic stem cell transplantation in non-Hodgkin lymphoma in Switzerland, 30 years of experience : Sooner is better | EJHaem | | | 2023 | 76 | 154 |
|
| CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients | Open forum infectious diseases | | | 2023 | 147 | 179 |
|
| CMV serostatus and T-cell repertoire diversity 5 years after allogeneic hematopoietic stem cell transplantation | Leukemia & lymphoma | | | 2023 | 83 | 132 |
|
| Graft versus host disease (GvHD) prevention in allogeneic hematopoietic stem cell transplantation: T cell depletion strategies to reduce GvHD risk while preserving graft versus tumor (GvT) effect | | | | 2023 | 141 | 4 |
|
| Longitudinal Detection of Twenty DNA and RNA Viruses in Allogeneic Hematopoietic Stem Cell Transplant Recipients Plasma | Viruses | | | 2023 | 164 | 197 |
|
| Salvage Treatment of Refractory HSV Oral Lesions with Pritelivir in Allogeneic Hematopoietic Cell Transplant Recipients | Antimicrobial agents and chemotherapy | | | 2023 | 114 | 579 |
|
| Hepatitis E Virus Infection Epidemiology in Recipients of Allogeneic Hematopoietic Cell Transplant | Open forum infectious diseases | | | 2023 | 76 | 153 |
|
| Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience : 2001-2020 | EJHaem | | | 2023 | 96 | 198 |
|
| Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress? | Open forum infectious diseases | | | 2022 | 280 | 292 |
|
| Human pegivirus-1 replication influences NK cell reconstitution after allogeneic haematopoietic stem cell transplantation | Frontiers in immunology | | | 2022 | 127 | 113 |
|
| Atypical pulmonary phaeohyphomycosis due to Aureobasidium spp. - case report and brief literature review | Swiss medical weekly | | | 2022 | 194 | 104 |
|
| Rhinovirus infections among hematopoietic stem cell transplant recipients: a pre-transplant dilemma? | Viruses | | | 2022 | 220 | 250 |
|
| Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients | Antimicrobial agents and chemotherapy | | | 2022 | 113 | 391 |
|
| Frequency and causes of antifungal treatment changes in allogeneic haematopoïetic cell transplant recipients with invasive mould infections | Mycoses | | | 2022 | 312 | 224 |
|
| Very severe immune thrombocytopenia following SARS-CoV-2 vaccination requiring splenectomy : a case report | Thrombosis journal | | | 2022 | 8 | 24 |
|
| Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT | Bone marrow transplantation | | | 2022 | 278 | 131 |
|
| Defibrotide Shows Efficacy in the Prevention of Sinusoidal Obstruction Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation : A Retrospective Study | Transplantation and cellular therapy | | | 2022 | 145 | 424 |
|
| T cell receptor sequencing reveals reduced clonal breadth of T-cell responses against SARS-CoV-2 after natural infection and vaccination in allogeneic hematopoietic stem cell transplant recipients | Annals of oncology | | | 2022 | 270 | 159 |
|
| When and how do we stop antifungal treatment for an invasive mould infection in allogeneic haematopoietic cell transplant recipients? | Mycoses | | | 2022 | 109 | 114 |
|
| Analysis of biological models to predict clinical outcomes based on HLA-DPB1 disparities in unrelated transplantation | Blood advances | | | 2021 | 329 | 159 |
|
| The EBMT Cytogenetic Risk Score maintains its prognostic significance in acute myeloid leukemia following allogeneic stem cell transplantation in a cohort with 40% of patients transplanted with in vitro partial T-cell depleted graft | Bone marrow transplantation | | | 2021 | 358 | 0 |
|
| Unmasking viral sequences by metagenomic next-generation sequencing in adult human blood samples during steroid-refractory/dependent graft-versus-host disease | Microbiome | | | 2021 | 415 | 410 |
|
| Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial | Annals of hematology | | | 2021 | 330 | 244 |
|
| Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study | Vaccines | | | 2021 | 213 | 340 |
|
| Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients | Bone marrow transplantation | | | 2021 | 348 | 2 |
|
| Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients | Immunity, inflammation and disease | | | 2021 | 380 | 252 |
|
| Clinical considerations of isavuconazole administration in high-risk hematological patients: a single-center 5-year experience | Mycopathologia | | | 2021 | 251 | 362 |
|
| Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients | Medical mycology | | | 2021 | 371 | 1 |
|
| Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir | Antimicrobial agents and chemotherapy | | | 2021 | 258 | 473 |
|
| Real-life considerations on antifungal treatment combinations for the management of invasive mold infections after allogeneic cell transplantation | Journal of Fungi | | | 2021 | 197 | 157 |
|
| Successful treatment of central nervous system lymphoproliferative disorder in a kidney-pancreas and stem cell transplanted patient using intrathecal rituximab | BMJ case reports | | | 2021 | 252 | 1 |
|
| Genetic T-cell receptor diversity at 1 year following allogeneic hematopoietic stem cell transplantation | Leukemia | | | 2020 | 412 | 369 |
|
| Torque Teno Virus as a potential biomarker for complications and survival after allogeneic hematopoietic stem cell transplantation | Frontiers in Immunology | | | 2020 | 569 | 244 |
|
| Intracellular Pathogen in the Cerebrospinal Fluid of an Allogeneic Hematopoietic Cell Transplant Recipient With Graft-Versus-Host Disease and Brain Lesions | Clinical infectious diseases | | | 2020 | 281 | 0 |
|
| Evaluation of Disease Risk Comorbidity Index after Allogeneic Stem Cell Transplantation in a Cohort with Patients Undergoing Transplantation with In Vitro Partially T Cell Depleted Grafts | Biology of Blood and Marrow Transplantation | | | 2020 | 346 | 325 |
|
| Optimal treatment duration of pseudomonas aeruginosa infections in allogeneic hematopoietic cell transplant recipients | Open Forum Infectious Diseases | | | 2020 | 471 | 167 |
|
| Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5-year analysis within the Swiss Transplant Cohort study | Transplant Infectious Disease | | | 2020 | 414 | 2 |
|
| Dynamics of Expression of Programmed Cell Death Protein-1 (PD-1) on T Cells After Allogeneic Hematopoietic Stem Cell Transplantation | Frontiers in Immunology | | | 2019 | 366 | 197 |
|
| Allograft and patient survival after sequential HSCT and kidney transplantation from the same donor-A multicenter analysis | American journal of transplantation | | | 2019 | 159 | 98 |
|
| Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis | The Journal of Infectious Diseases | | | 2019 | 289 | 0 |
|
| Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation | Leukemia and Lymphoma | | | 2018 | 552 | 2 |
|
| Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016 | Swiss Medical Weekly | | | 2018 | 511 | 332 |
|
| Impact of T-cell depletion on outcome of patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome | Bone Marrow Transplantation | | | 2018 | 466 | 0 |
|
| Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study | BMC Infectious Diseases | | | 2018 | 551 | 340 |
|
| Human pegivirus persistence in the human blood virome after allogeneic haematopoietic stem cell transplantation | Clinical Microbiology and Infection | | | 2018 | 1,405 | 648 |
|
| Torque Teno Virus Load and Acute Rejection after Orthotopic Liver Transplantation | Transplantation | | | 2017 | 856 | 0 |
|
| FLT3-ITD mutations do not impact the outcome of patients allografted with partial T-cell depleted grafts for AML with normal cytogenetics in first complete remission | Hematological oncology | | | 2017 | 549 | 3 |
|
| Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with a non-T-cell-depleted graft when stratified by the refined disease risk index | Bone marrow transplantation | | | 2016 | 660 | 2 |
|
| Excellent outcome with a high proportion of mixed chimerism in patients with severe aplastic anemia treated with partially T-cell-depleted peripheral hematopoietic stem cell transplants | Bone marrow transplantation | | | 2016 | 689 | 4 |
|
| Immunological Basis of Bone Marrow Failure after Allogeneic Hematopoietic Stem Cell Transplantation | Frontiers in Immunology | | | 2016 | 530 | 328 |
|
| Torque teno virus in patients undergoing allogeneic hematopoietic stem cell transplantation for hematological malignancies | Bone marrow transplantation | | | 2016 | 519 | 2 |
|
| Transplantation de cellules souches hématopoïétiques périphériques partiellement déplétées en lymphocytes T chez les patients avec anémie aplastique sévère : excellents résultats et incidence élevée de chimérisme mixte | | | | 2016 | 811 | 688 |
|
| Complete and sustained remission of spondyloarthritis after allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome | Joint bone spine | | | 2015 | 623 | 2 |
|
| Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies | Bone marrow research | | | 2015 | 596 | 247 |
|
| In-Hospital Transfer Is a Risk Factor for Invasive Filamentous Fungal Infection among Hospitalized Patients with Hematological Malignancies: A Matched Case-Control Study | Infection control and hospital epidemiology | | | 2015 | 630 | 1 |
|
| NK Cell Functional Impairment after Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Reduced Levels of T-bet and Eomesodermin | The Journal of immunology | | | 2015 | 570 | 3 |
|
| Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies | Bone marrow research | | | 2015 | 727 | 403 |
|
| Validation of the disease risk index for outcome of patients undergoing allogeneic hematopoietic stem cell transplantation after T cell depletion | Biology of blood and marrow transplantation | | | 2014 | 632 | 1 |
|
